摘要
第二代(非典型)抗精神病药鲁拉西酮对多巴胺D_(2)受体、5-羟色胺5-HT_(2A)、5-HT_(7)受体均有高亲和性,多项临床试验显示其可改善精神分裂症患者精神病性症状、情感症状、认知症状,且具有对糖脂代谢指标、催乳素影响小等安全性优势。本文结合鲁拉西酮研究证据及海峡两岸专家用药经验撰写为专家建议,以期为鲁拉西酮临床应用提供参考。
Lurasidone is a second-generation antipsychotic drug which has a high affinity for dopamine D_(2),serotonin 5-HT_(2A) and 5-HT_(7) receptors.Several clinical trials in patients with schizophrenia indicated lurasidone’s effect on improving psychotic symptoms,affective symptoms and cognitive symptoms,and it also manifested fewer side effects on metabolic indicators.Based on the evidence from previous studies on lurasidone and clinical experiences of experts from China Mainland and Taiwan,this experts’advice has been formed with an aim to provide guidance on the use of lurasidone in clinical practice.
作者
司天梅
赵靖平
于欣
方贻儒
梅其一
刘靖
邱南英
张明永
林式榖
杨甫德
SI Tianmei;ZHAO Jingping;YU Xin;FANG Yiru;MEI Qiyi;LIU Jing;CHIU Nan-Ying;CHONG Mian-Yoon;LIN Shih-Ku;YANG Ride(Peking University Sixth Hospital,Peking University Institute of Mental Health,National Clinical Reseach Center for Mental Health(Peking University Sixth Hospital),Beijing 100083,China;Second Xiangya Hospital of Cental Sout University,National Clinical Reseach Center for Mental Healtii(Second Xiangya Hospital),Changsha 410011,China;Shanghai Jiao Tong University School of Medicine,Shanghai Mental Healti Center,Shanghai 200030,China;Suzhou Guangi Hospital,Suzhou 215123,Jiangsu Province,China;Lukang Christian Hospital,Changhua 50544,Taiwan Province,China;Kaohsiung Chang Gung Memorial Hospital,Kaohsiung 83301,Taiwan Province,China;Linkou Chang Gung Memorial Hospital,Taoyuan 33375,Taiwan Povince,China;Beijing Huilongguan Hospital,Beijing 100096,China)
出处
《中国心理卫生杂志》
CSCD
北大核心
2022年第6期457-464,共8页
Chinese Mental Health Journal
